Institut De Cancerologie De Lorraine
Verified site
Vandoeuvre Les Nancy, France
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial focuses on patients with metastatic colorectal cancer who have specific genetic characteristics - namely RAS and B-RAF wild-type mutations, which are determined through a blood test analyzing circulating cell-free DNA. The study compares two different combination treatments: FOLFIRINOX plus panitumumab versus mFOLFOX6 plus panitumumab.
The treatment combinations include several medications given through infusion or injection. The first combination consists of oxaliplatin, irinotecan, fluorouracil, folinic acid (or calcium levofolinate), and panitumumab. The second combination includes some of the same medications but without irinotecan. These medications are types of chemotherapy drugs, with panitumumab being a targeted therapy that specifically fights cancer cells.
The main purpose of this study is to evaluate how well patients respond to these treatment combinations, specifically looking at whether the cancer completely disappears after treatment. The study will monitor patients' responses through regular medical imaging and blood tests to track the effectiveness of the treatments. Patients will receive up to 12 rounds of treatment, with regular check-ups to monitor their health and the cancer's response to therapy.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
16 criteria
15 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Vandoeuvre Les Nancy, France
Dijon, France
Caen, France
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a targeted therapy medication that works by blocking a specific protein called EGFR on cancer cells. It's used to treat colorectal cancer by helping to stop cancer cells from growing and spreading.
is a combination chemotherapy treatment that includes three different cancer-fighting drugs: fluorouracil, irinotecan, and oxaliplatin. This combination works together to kill cancer cells and prevent them from multiplying.
is a modified combination chemotherapy treatment that includes fluorouracil, leucovorin, and oxaliplatin. This combination is commonly used to treat colorectal cancer by attacking cancer cells in different ways to stop their growth and spread.
A targeted biological therapy administered through intravenous infusion that is used in the treatment of metastatic colorectal cancer, specifically in patients with wild-type RAS and B-RAF genes. This monoclonal antibody works by targeting and blocking the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from receiving growth signals and thus inhibiting tumor growth. As a first-line treatment option, it is often combined with chemotherapy regimens such as FOLFIRINOX or FOLFOX to enhance treatment effectiveness in selected patients.
A combination chemotherapy regimen administered intravenously that consists of four drugs: fluorouracil, leucovorin, irinotecan, and oxaliplatin. This intensive treatment protocol is used in the management of metastatic colorectal cancer and works through multiple mechanisms to prevent cancer cell division and growth. The combination demonstrates enhanced effectiveness compared to single-agent treatments, though it may have more side effects than simpler chemotherapy regimens.
A chemotherapy combination administered intravenously that includes fluorouracil, leucovorin, and oxaliplatin (specifically mFOLFOX6 in this context). This widely-used treatment protocol for metastatic colorectal cancer works by interfering with cancer cell DNA replication and division processes. The treatment is typically given in cycles and represents a standard care option that balances effectiveness with manageable side effects.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.